ADAM17 and interstitial lung disease: The results were biased due to the small number of serum samples from CTD‐ILD patients, but the elevated expression of ADAM17 in ILD patients is not the first time it has been confirmed in this study, and more studies have reported the same findings [64, 65], which increased the credibility of the results.